Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Fourth Quarter & Year Ended Septem...
November 15 2013 - 8:30AM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs in the infectious disease field, today
announced that it plans to report its fiscal fourth quarter and
September 30 year end financial results before the U.S. markets
open on November 25, 2013. Enanta management will host a conference
call at 8:30 a.m. ET to discuss these results.
Conference Call and Webcast Information
To participate in the live conference call, please dial (855)
840-0595 in the U.S. or (518) 444-4814 for international callers. A
replay of the conference call will be available starting at
approximately 11:30 a.m. Eastern time on November 25, 2013, through
11:59 p.m. Eastern time on November 29, 2013 by dialing (855)
859-2056 from the U.S. or (404) 537-3406 for international callers.
The passcode for both the live call and the replay is 10354107. A
live audio webcast of the call will be accessible at www.enanta.com
for no more than 30 days. Please visit the Investor home page of
the website and search for calendar of events. A replay of the
webcast will be available on www.enanta.com approximately two hours
following the live webcast.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs in the infectious disease field. Enanta is discovering, and
in some cases developing, novel inhibitors designed for use against
the hepatitis C virus (HCV). These inhibitors include members of
three direct acting antiviral (DAA) inhibitor classes – protease
(partnered with AbbVie), NS5A (partnered with Novartis) and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for
the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024
